283 related articles for article (PubMed ID: 2458208)
1. Sublingual absorption of selected opioid analgesics.
Weinberg DS; Inturrisi CE; Reidenberg B; Moulin DE; Nip TJ; Wallenstein S; Houde RW; Foley KM
Clin Pharmacol Ther; 1988 Sep; 44(3):335-42. PubMed ID: 2458208
[TBL] [Abstract][Full Text] [Related]
2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
3. Placental trophoblast transfer of opioids following exposures to individual or mixtures of opioids
Mortensen NP; Caffaro MM; Snyder RW; Yueh YL; Fennell TR
Exp Biol Med (Maywood); 2019 Jul; 244(10):846-849. PubMed ID: 31091988
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats.
Pypendop BH; Ilkiw JE; Shilo-Benjamini Y
J Vet Pharmacol Ther; 2014 Jun; 37(3):295-300. PubMed ID: 24236993
[TBL] [Abstract][Full Text] [Related]
5. Rational use of sublingual opioids in palliative medicine.
Reisfield GM; Wilson GR
J Palliat Med; 2007 Apr; 10(2):465-75. PubMed ID: 17472518
[TBL] [Abstract][Full Text] [Related]
6. [Opioid switch and change of route of administration in cancer patients treated by morphine].
Michenot N; Rostaing S; Baron L; Faure S; Jovenin N; Hubault P; Delorme T; Collin E; Filbet M; Chvetzoff G; Delorme C; Minello C; Magnet M; Ammar D; Krakowski I; Poulain P
Bull Cancer; 2018 Nov; 105(11):1052-1073. PubMed ID: 30274680
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study.
Parikh N; Goskonda V; Chavan A; Dillaha L
Clin Drug Investig; 2013 Jun; 33(6):391-400. PubMed ID: 23605506
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability of sublingual buprenorphine.
Mendelson J; Upton RA; Everhart ET; Jacob P; Jones RT
J Clin Pharmacol; 1997 Jan; 37(1):31-7. PubMed ID: 9048270
[TBL] [Abstract][Full Text] [Related]
9. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers.
Jönsson M; Mundin G; Sumner M
Eur J Pharm Sci; 2018 Sep; 122():125-133. PubMed ID: 29940217
[TBL] [Abstract][Full Text] [Related]
11. Effect of pH on sublingual absorption of oxycodone hydrochloride.
Al-Ghananeem AM; Malkawi AH; Crooks PA
AAPS PharmSciTech; 2006 Mar; 7(1):E23. PubMed ID: 16584154
[TBL] [Abstract][Full Text] [Related]
12. Opioid addicts at admission vs. slow-release oral morphine, methadone, and sublingual buprenorphine maintenance treatment participants.
Giacomuzzi S; Kemmler G; Ertl M; Riemer Y
Subst Use Misuse; 2006; 41(2):223-44. PubMed ID: 16393744
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
[TBL] [Abstract][Full Text] [Related]
14. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.
Gunderson EW; Hjelmström P; Sumner M;
Clin Ther; 2015 Oct; 37(10):2244-55. PubMed ID: 26412801
[TBL] [Abstract][Full Text] [Related]
15. Opioid Concentrations in Oral Fluid and Plasma in Cancer Patients With Pain.
Heiskanen T; Langel K; Gunnar T; Lillsunde P; Kalso EA
J Pain Symptom Manage; 2015 Oct; 50(4):524-32. PubMed ID: 25242020
[TBL] [Abstract][Full Text] [Related]
16. Opioid selective antinociception following microinjection into the periaqueductal gray of the rat.
Morgan MM; Reid RA; Stormann TM; Lautermilch NJ
J Pain; 2014 Nov; 15(11):1102-1109. PubMed ID: 25106089
[TBL] [Abstract][Full Text] [Related]
17. [Understanding Oral and Nasal Mucosal Absorption of Fentanyl, and Rectal Absorption of Buprenorphine].
Shimoyama N; Shimoyama M; Kubota Y; Kato Y
Masui; 2015 Nov; 64(11):1160-5. PubMed ID: 26689067
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.
Harris DS; Mendelson JE; Lin ET; Upton RA; Jones RT
Clin Pharmacokinet; 2004; 43(5):329-40. PubMed ID: 15080765
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain.
Shimoyama N; Gomyo I; Teramoto O; Kojima K; Higuchi H; Yukitoshi N; Ohta E; Shimoyama M
Jpn J Clin Oncol; 2015 Feb; 45(2):189-96. PubMed ID: 25378647
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
